Biologic and Medical Imaging Reagents: Global Markets
The global market for biological imaging reagents was valued at $13.2 billion in 2016. This market will grow from $14.4 billion in 2017 to nearly $23.9 billion by 2022 with a compound annual growth rate (CAGR) of 10.6% for the period of 2017-2022.
- 32 data tables and 76 additional tables
- An overview of the global markets for biologic and medical imaging reagents
- Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
- A comprehensive analysis of imaging techniques as an important tool in medical diagnostic procedures
- Coverage of current and future strategies within the medical imaging technology market
- A look at classifications, comparisons, advantages, and disadvantages of these types of diagnostic methods
- A detailed analysis of the industry structure
- Profiles of major players in the industry
Topics covered in this report include:
- Fluorescent dyes and probes.
- Fluorescent proteins.
- Nanoparticles, including quantum dots.
- Imaging radiopharmaceuticals.
- Contrast reagents for X-ray/CT, MRI and ultrasound.
Topics not covered in this report include:
- Drug delivery.
- Supramolecular chemistry.
- Imaging instruments and software.
The scope of the study includes the biological imaging reagents that are already commercialized or likely to be commercialized within the next five years. Fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals are studied. Both the in vivo and in vitro market segments are included. Each technology is analyzed to determine its market status, impact on future market segments and forecast growth from 2017 through 2022. Technology status and market driving forces are also discussed.
BCC Research examines imaging reagent producers and the industry structure in specialized segments of the industry. We also review industry alliances and acquisitions, and the use of biological imaging reagents in key diagnostics and research and development (R&D) tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis. The markets for novel biological imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents, are analyzed, and the main companies in these fields are highlighted.
Bhavna Joshi has more than six years of domain experience. In addition to business research and consulting, she has conducted corporate briefings for top players in a wide range of market segments. She holds an MBA in the marketing and finance from Chennai University and has worked with major market research firms.
Bhavna Joshi has authored several market research studies on subjects in the healthcare domain, including:
- Healthcare tracking technologies.
- Molecular diagnostics market.
- High-growth markets in healthcare and life sciences.
- Adoption rates and analysis of over-the-counter (OTC) diabetic medicines and supplements.
- Radio frequency identification (RFID), real-time locating systems (RTLS), internet protocol (IP) surveillance and other emerging technologies in the healthcare domain.
The global medical imaging market was valued at $25.4 billion in 2011 and should reach $26.7 billion in 2012. Total market value is expected to reach nearly $34.1 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5%.
- Global revenue of the imaging market was worth approximately $21.8 billion in 2008, a figure that further increased to $22.6 billion in 2009. This is projected to reach $29 billion in 2014, at a CAGR of 5.1% between 2009 and 2014.
- The largest segment X-ray and computed tomography was nearly $9.2 billion in 2008; this further increased to $9.3 billion in 2009, this is projected to reach $11.3 billion in 2014, for a 5-year CAGR of 3.9%.
- The Second largest segment ultrasound was nearly $5 billion in 2008; this further increased to $5.1 billion in 2009, this is projected to reach $6.1 billion in 2014, for a 5-year CAGR of 3.4%.
The U.S. market for medical imaging reagents and analysis tools is valued at a little more than $4.9 billion in 2006 and is expected to grow at an average annual growth rate of 11.9% to reach over $8.4 billion in 2011.
Imaging reagents currently comprise the largest segment with a value of $2.97 billion in 2006. Medical imaging reagents are expected to increase at an average annual rate of 10.5% to reach $4.9 billion in 2011. The market for imaging reagents is currently led by radiopharmaceuticals for nuclear medicine imaging. The market for these reagents was over $1 billion in 2006 and is expected to grow with an average annual rate of 11.8% to surpass $1.7 billion in 2011. Ultrasound imaging reagents are expected to experience the most significant growth with an average annual rate of 36% to reach $252.8 million in 2011.
Within the image analysis market, tools for the analysis of ultrasound images were $190.5 million in 2006 and are expected to grow at an average annual rate of 13.6% to reach $360.6 in 2011.
The total U.S. market for imaging reagents was $2.8 billion in 2003 and is expected to grow to $ 3.9 billion by 2008 at an AAGR (average annual growth rate) of 6.9%.
While currently the largest market, the x-ray segment appears stagnant, increasing at a very low rate, while the ultrasound market is rising rapidly with many new developments.
The MRI reagent market is the prime market for today since a good number of products are available and many more are in the pipeline.
Sales of reagents for cardiovascular applications were $770 million in 2003 and are expected to rise at an AAGR of 7.0%.
Reagents used in oncology and GIT are rising at AAGRs of 7.0% and 5.1%, respectively.